drugset / Trial / NCT00893841
Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride
Phase 2
Completed
96 enrolled
Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.
AstraZeneca · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is designed to assess the use of pramipexole dihydrochloride and quetiapine (Seroquel) XR as combination therapy for bipolar depression. The proposed benefit of the combination therapy investigated in this study is improved treatment of bipolar depression.
Timeline
- Start
- 2009-02
- Primary completion
- 2013-01
- Completion
- 2013-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pramipexole | Unknown | 0.25 mg | — |
| Subject | Pramipexole | Unknown | 0.5 mg | — |
| Comparator | Quetiapine | Small molecule | 300 mg | — |